Current status of haploidentical stem cell transplantation for leukemia

Journal of Hematology and Oncology

Volumn 1, Issue 1, 2008, Pages

  Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; DONOR; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; LEUKEMIA; METHODOLOGY; REVIEW; STEM CELL TRANSPLANTATION;

GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 68049097933     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-1-27     Document Type: Article

References (62)

1. Huang XJ, Xu LP, Liu KY, et al.: HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008:1-12.
2. Hansen JA, Petersdorf E, Martin PJ, Anasetti C: Hematopoietic stem cell transplants from unrelated donors. Immunol Rev 1997, 157:141-151. (Pubitemid 27303126)
3. Howe CWS, Radde-Stepaniak T: Hematopoietic cell donor registries. In Hematopoietic cell transplantation 2nd edition. Edited by: Thomas ED, Blume KG, Forman SJ. Malden, MA: Blackwell Science; 1999:503-512.
4. Anasetti C: Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 2000, 14:502-504. (Pubitemid 30142880)
5. Aversa F, Velardi A, Tabilio A, et al.: Haploidentical stem cell transplantation in leukemia. Blood Rev 2001, 15:111-119. (Pubitemid 32999196)
6. Rocha V, Labopin M, Sanz G, et al.: Transplants of umbilical cord blood or bone marrow from unrelated donors in adult with leukemia. N Engl J Med 2004, 351:2276-2258.
7. Ruggeri L, Capanni M, Casucci M: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell trasplantation. Blood 1999, 94:333-339. (Pubitemid 29300166)
8. Ruggeri L, Capanni M, Urbani E, et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematoopoietic transplants. Science 2002, 295:2097-2100. (Pubitemid 34229476)
9. Zhao XY, Huang XJ, Liu KY, et al.: Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipient. Eur J Haematol 2007, 78:338-346.
10. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, et al.: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313(13):765-771. (Pubitemid 15232310)
11. Huang XJ, Liu DH, Liu KY, et al.: Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
12. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al.: Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997, 89:3864-3872. (Pubitemid 27227113)
13. Mehta J, Singhal S, Gee AP, et al.: Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 2004, 33:389-396. (Pubitemid 38313087)
14. Sierra J, Storer B, Hansen JA, et al.: Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997, 89:4226-4235. (Pubitemid 27220974)
15. Reisner Y, Kapoor N, Kirkpatrick D, et al.: Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractioned by soybean agglutinin and sheep red blood cells. Blood 1983, 61:341-348. (Pubitemid 13137655)
16. Aversa F, Tabilio A, Terenzi A, et al.: Successful engraftment of T cell-depleted haploidentical 'three-loci' incompatibal transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84:3948-3955.
17. Aversa F, Tabilio A, Velardi A, et al.: Treatment high-risk acute leukemia with T-cell-depleted stem cells from related donors with on fully mismatched HLA haplotype. N Engl J med 1998, 339:1186-1193. (Pubitemid 28482127)
18. Aversa F, Terenzi A, Tabilio A, et al.: Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J clini Oncol 2005, 23:3447-3454.
19. Meijer E, Slaper-Cortenbach IC, Thijsen SF, et al.: Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation form matched unrelated donors due to a change of T cell depletion technique. Bone Marrow transplant 2002, 29:335-339. (Pubitemid 34229039)
20. Liu D, Tammik C, Zou JZ, et al.: Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Clin Transplant 2004, 18:518-524. (Pubitemid 39264347)
21. Aversa F, Reisner Y, Martelli MF: The haploidentical option for high-risk haematological malignancies. Blood cells Mol Dis 2008, 40:8-12. (Pubitemid 350192297)
22. Lang P, Greil J, Bader P, et al.: Long-term outcome after haploidentical stem cell transplantation in children. Blood cells Mol Dis 2004, 33:281-87. (Pubitemid 39446500)
23. Lang P, Bader P, Schumm M, et al.: Transplantation of a combined CD133+ and CD34+selected progenitor cells from alternative donors. Br J Haematol 2004, 124:72-79. (Pubitemid 38021625)
24. Bethge WA, Faul C, Bornhauser M, et al.: Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/ CD19depletion and reduced intensity conditioning; an update. Blood Cell Mol Dis 2008, 40:13-19. (Pubitemid 350192298)
25. Handgretinger R, Chen X, Pfeifer M, et al.: Feasibility and outcome of reduced intensity conditioning in haploidentical transplantation. Ann NY Acad Sci 2007, 1106:279-289. (Pubitemid 47443058)
26. Dey BR, Spizer TR: Current status of haploidentical stem cell transplantation. Br J Hemato 2006, 135:423-437. (Pubitemid 44583409)
27. Solomon SR, Mielke S, Savani BN, et al.: Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005, 106:1123-1129. (Pubitemid 41076463)
28. Amrolia PJ, Muccioli-Casadei G, Huls H, et al.: Adoptive immunotherapy with allodepleted donor T cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006, 108:1797-1808. (Pubitemid 44394986)
29. Hartwig UF, Robbers M, Wickenhauser C, Huber C: Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 99(8):3041-9. 2002 Apr 15 (Pubitemid 34525397)
30. Hossain MS, Roback JD, Wang F, Waller EK: Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol 2008, 180:6892-902.
31. Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W: Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008, 14:99-109. (Pubitemid 350286744)
32. Liu DH, Huang XJ, Liu KY, et al.: Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 2008, 14:469-477.
33. Huang XJ, Chang YJ, Zhao XY: A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSFmobilized peripheral blood grafts. Haematologica 2005, 90(5):715-716.
34. Chen SH, Li X, Huang XJ: Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004, 79:178-184. (Pubitemid 38281820)
35. Huang XJ, Chang YJ, Zhao XY: In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004, 89:1517-1524. (Pubitemid 39643521)
36. O'donnell PV, Luznik L, Jones RJ, et al.: Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
37. Fuchs EJ, Lunzik L, Chen AR, et al.: Post-transplantation cyclophosphamide (Cy) reduces graft rejection and graft-versushost disease (GVHD) after non-myeloablative, partially HLA-mismatched (haploidentical) bone marrow transplantation (BMT). Blood 2004, 104:437a.
38. Rizzieri DA, Koh LP, Long GD, et al.: Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007, 25:690-697. (Pubitemid 350002925)
39. Ogawa H, Ikegame K, Yoshihara S, et al.: Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning Biol Blood Marrow Transplant. 2006, 12:1073-1084.
40. Guinan EC, Boussiotis VA, Neuberg D, et al.: Transplantation of anergic histoincompatibal bone marrow allografts. New Engl J Med 1999, 340:1704-1714. (Pubitemid 29252598)
41. Huang XJ, Guo NL, Ren HY, et al.: An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J (Engl) 2003, 116(5):736-741.
42. Huang XJ, Liu DH, Xu LP, et al.: Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006, 20:365-368.
43. Dazzi F, Szydlo RM, Cross NC, et al.: Durability of responses following donor lymphocyte infusions for patients who relaspse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000, 96:2712-2716.
44. Porter DL, Collins RH Jr, Hardy C, et al.: Treatment ofrelapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000, 95:1214-1221. (Pubitemid 30099829)
45. Lewalle P, Triffet A, Delforge A, et al.: Donor lymphocyte infusion in adult haploidentical transplant: a dose finding study. Bone marrow Transplant 2003, 31:39-44. (Pubitemid 36181820)
46. Or R, Hadar E, Bitan M, et al.: Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1295-1301. (Pubitemid 44858263)
47. Huang XJ, Liu DH, Liu KY, et al.: Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem ell transplantation for prophylaxis for relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008, 28:276-283.
48. Soiffer RJ, Alyea EP, Hochberg E, et al.: Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002, 8:625-632. (Pubitemid 35446754)
49. Passweg JR, Ticheli A, Meyer-Monard S, et al.: Purified donor NKlymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838. (Pubitemid 39530014)
50. Passweg JR, Stern M, Koehl U, et al.: Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 2005, 35:637-643. (Pubitemid 40520947)
51. Huang XJ, Liu DH, Liu KY, et al.: Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/ haploidentical T-cell-replete hematopoietic stem cell transplantation. Hematologica 2007, 92:414-417.
52. Bignon JD, Gagne K: KIR matching in Hematopoietic stem cell transplantation. Curr Opin Immunol 2005, 17:553-559. (Pubitemid 41207961)
53. Leung W, Iyengar R, Triplett B, et al.: Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174:6540-6545. (Pubitemid 40663849)
54. Bornhauser M, Schwerdtfeger R, Martin H, et al.: Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004, 103:2860-2862. (Pubitemid 38393053)
55. Lowe EJ, Turner V, Handgretinger R, et al.: T-cell alloreactivity dominates natural killer cell alloreactivity in minimally Tcell-depleted HLA-non-identical pediatric bone marrow transplantation. Br J Haematol 2003, 123:323-326. (Pubitemid 37305068)
56. Cooley S, McCullar V, Wangen R, et al.: KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376. (Pubitemid 41775950)
57. Hoffman P, Eder R, Kunz-Schughart LA, et al.: Large-scale in vitro expansion of polyclonal human CD4+ CD25high regulatory T cells. Blood 2004, 104:895-903. (Pubitemid 38970590)
58. Clark FJ, Gregg R, Piper K, et al.: Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004, 103:2410-2416. (Pubitemid 38326268)
59. Lowsky R, Takahashi T, Liu YP, et al.: Protective conditioning for acute graft-versus-host disease. New Engl J Medicine 2005:1321-1331. (Pubitemid 41362700)
60. Le Blank K, Rasmusson I, Sundberg B, et al.: Treatment of sever acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441. (Pubitemid 38586721)
61. Kato S, Yabe H, Yasui M, et al.: allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haploidentical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood. Bone Marrow Transplant 2000, 26:1281-1290. (Pubitemid 32098046)
62. Walker I, Shehata N, Cantin G, et al.: Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis 2004, 33:222-226. (Pubitemid 39446490)